SCHEMBL4964795

SCHEMBL4964795

NC(=O)c1c(-c2ccc(NC(=O)Nc3cc(C(F)(F)F)ccc3Cl)cc2)csc1N

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RIPK1 Q13546 3/20 0.58
FLT1 P17948 4/20 0.56
TEK Q02763 1/20 0.56
KIT P10721 6/20 0.52
FLT3 P36888 6/20 0.52
NTRK1 P04629 3/20 0.52
ABL1 P00519 3/20 0.52
LCK P06239 3/20 0.52
FYN P06241 3/20 0.52
CSF1R P07333 3/20 0.52
LYN P07948 3/20 0.52
BLK P51451 3/20 0.52
PLK4 O00444 2/20 0.52
AURKA O14965 2/20 0.52
MAPK13 O15264 2/20 0.52
PDPK1 O15530 2/20 0.52
JAK2 O60674 2/20 0.52
CHEK2 O96017 2/20 0.52
INSR P06213 2/20 0.52
MET P08581 2/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4964462 0.90 KIT (0.64) RIPK1FLT1TEKKITFLT3
SCHEMBL4966551 0.85 RIPK1 (0.56) RIPK1FLT1TEKKITFLT3
SCHEMBL4480358 0.79 RIPK1 (0.53) RIPK1FLT1TEKKITFLT3
SCHEMBL4962802 0.79 ANO1 (0.49) FLT1TEKKITFLT3NTRK1
SCHEMBL6536099 0.77 MEN1 (0.57) RIPK1FLT1TEKTP53GAA
SCHEMBL4257211 0.77 RIPK1 (0.53) RIPK1FLT1TEKKITFLT3
SCHEMBL4964671 0.77 KDR (0.55) FLT1KITFLT3NTRK1ABL1
SCHEMBL4962777 0.76 KIT (0.61) RIPK1FLT1TEKKITFLT3
SCHEMBL19048693 0.76 KDR (0.62) FLT1TEKKITFLT3NTRK1
SCHEMBL4262663 0.76 RIPK2 (0.58) RIPK1FLT1TEKNTRK1LCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1436279-B8 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORP (US) 2008-10-29 EP claimed
EP-1436279-B1 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORP (US) 2008-08-13 EP claimed
US-7179836-B2 Chemical compounds SMITHKLINE BEECHAM CORPORATION (US) 2007-02-20 US claimed
EP-1436279-A4 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORP (US) 2005-10-26 EP claimed
US-20040192941-A1 Chemical compounds SMITHKLINE BEECHAM CORPORATION 2004-09-30 US claimed
EP-1436279-A1 CHEMICAL COMPOUNDS SmithKline Beecham Corporation (US) 2004-07-14 EP claimed
WO-2003027093-A1 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2003-04-03 WO claimed
EP-1436279-B8 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORP (US) 2008-10-29 EP disclosed
EP-1436279-B1 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORP (US) 2008-08-13 EP disclosed
EP-1436279-B1 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORP (US) 2008-08-13 EP disclosed
US-7179836-B2 Chemical compounds SMITHKLINE BEECHAM CORPORATION (US) 2007-02-20 US disclosed
US-7179836-B2 Chemical compounds SMITHKLINE BEECHAM CORPORATION (US) 2007-02-20 US disclosed
US-7179836-B2 Chemical compounds SMITHKLINE BEECHAM CORPORATION (US) 2007-02-20 US disclosed
EP-1436279-A4 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORP (US) 2005-10-26 EP disclosed
US-20040192941-A1 Chemical compounds SMITHKLINE BEECHAM CORPORATION 2004-09-30 US disclosed
EP-1436279-A1 CHEMICAL COMPOUNDS SmithKline Beecham Corporation (US) 2004-07-14 EP disclosed
WO-2003027093-A1 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2003-04-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040192941-A1 Chemical compounds TPMT, TST, CYP11B2 RIPK1 4198/4885FLT1 3362/4885TEK 3511/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.